ArticleFrontiers in oncology2026
Network connectome analysis of multi omics data identifies molecular markers of recurrence and grade progression in meningioma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meningiomas are usually benign, but some behave aggressively with early recurrence. Histopathological grading alone often fails to predict outcomes. We developed a network connectome and clustering framework that integrates DNA methylation, RNA-seq, and proteomic data to identify molecular interaction patterns linked to recurrence and grade progression. Methods: Using genome-wide methylation, transcriptomic, and proteomic profiles, we constructed multi-layer connectome networks representing inter-omic correlations. Nodes and edges were analyzed by centrality and clustering metrics to detect key molecular modules associated with clinical outcomes. Results: Distinct network clusters differentiated recurrent and higher-grade meningiomas from indolent ones. A total of 29 methylation, 32 gene, and 33 protein features were significantly related to recurrence; 70, 61, and 56 features were linked to grade progression. Recurrent tumors showed increased inter-omic connectivity and altered hub distributions. LINC01397 emerged as a recurrent hub across omic layers, suggesting its role as a potential unified biomarker. Conclusion: Our connectome-based multi-omics analysis reveals that meningioma aggressiveness is driven by coordinated molecular interactions rather than single-omic alterations. This systems-level approach provides a compact, data-driven framework for predicting recurrence and grade, supporting precision risk stratification in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.